Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pasithea Therapeutics Corp (NQ: KTTA ) 6.090 +0.240 (+4.10%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Pasithea Therapeutics Corp Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 June 01, 2023 EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END Via FinancialNewsMedia Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics December 07, 2022 From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC Via Business Wire Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics November 22, 2022 From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC Via Business Wire Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis October 03, 2022 Learn More about Pasithea Therapeutics by gaining access to the latest research report Via TheNewswire.com Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics October 13, 2022 From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC Via Business Wire Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028 October 12, 2022 Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... Via FinancialNewsMedia Exposures COVID-19 Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022 September 29, 2022 Via Get News Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors September 28, 2022 From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC Via Business Wire Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics September 06, 2022 From Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC Via Business Wire Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting August 24, 2022 From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC Via Business Wire Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029 August 11, 2022 Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... Via FinancialNewsMedia Exposures COVID-19 Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting August 05, 2022 From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC. Via Business Wire Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5 June 23, 2022 From Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC Via Business Wire Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026 June 22, 2022 Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... Via FinancialNewsMedia PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article May 05, 2022 Via Investor Brand Network Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions March 08, 2022 Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric... Via FinancialNewsMedia Topics Economy Exposures Economy Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028 February 03, 2022 Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,... Via FinancialNewsMedia Exposures COVID-19 Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally February 24, 2022 Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... Via FinancialNewsMedia Exposures COVID-19 Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression November 23, 2021 Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market.... Via FinancialNewsMedia Exposures COVID-19 Use of Ketamine for Mental Disorders Rising While New Therapies Emerge November 17, 2021 Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... Via FinancialNewsMedia Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention October 27, 2021 Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... Via FinancialNewsMedia Exposures Product Safety Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market October 14, 2021 Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the... Via FinancialNewsMedia Exposures COVID-19 Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028 October 11, 2021 Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,... Via FinancialNewsMedia SmallCapsDaily: Pasithea Therapeutics Emerges as a Major Player in the Biotech Industry October 04, 2021 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.